Skip to main content

Abstract

This chapter discusses the genetics, metabolic actions, substrates, inducers, and inhibitors of cytochrome P450 3A4.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dresser GK, Spence JD, et al. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38(1):41–57.

    Article  PubMed  CAS  Google Scholar 

  2. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 2006;78(18):2131–45.

    Article  PubMed  CAS  Google Scholar 

  3. Ohno Y, Hisaka A, et al. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007;46(8):681–96.

    Article  PubMed  CAS  Google Scholar 

  4. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Phamacol Exp Ther. 1997;283:1552–62.

    CAS  Google Scholar 

  5. Sandson NB. Drug-Drug Interaction Primer: A Compendium of Case Vignettes for the Practicing Clinician. Washington DC: American Psychiatric Publishing, Inc; 2007.

    Google Scholar 

  6. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P4503A in psychopharmacology. J Clin Psychopharmacol. 1995;15:387–8.

    Article  PubMed  CAS  Google Scholar 

  7. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990;264:2788–90.

    Article  PubMed  CAS  Google Scholar 

  8. Tsai WC, Tsai LM, Chen JH. Combined use of astemizole and ketoconazole resulting in Torsades de pointes. J Formos Med Assoc. 1997;96:144–6.

    PubMed  CAS  Google Scholar 

  9. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis (letter). Ann Intern Med. 1988;109:682–3.

    Article  PubMed  CAS  Google Scholar 

  10. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA. 1988;260:239–41.

    Article  PubMed  CAS  Google Scholar 

  11. Biesenbach G, Janko O, Stuby U, et al. Myoglobinuric renal failure due to long-standing lovastatin therapy in a patient with pre-existing chronic renal insufficiency. Nephrol Dial Transplant. 1996;11:2059–60.

    Article  PubMed  CAS  Google Scholar 

  12. Hino I, Akama H, Furuya T, et al. Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease. Arthritis Rheum. 1996;39:1259–60.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jennifer DeCou MD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

DeCou, J., Birgenheier, N., Dull, R.O. (2015). CYP3A4: The Workhorse. In: Marcucci, C., et al. A Case Approach to Perioperative Drug-Drug Interactions. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7495-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-7495-1_7

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-7494-4

  • Online ISBN: 978-1-4614-7495-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics